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according to the AIT’s criteria could result in better clinical outcomes with little 
impact on the annual budget.
PND12
A BuDget ImPAct ANAlysIs Of the cOchrANe cOllABOrAtION revIew Of 
fIrst-lINe treAtmeNts fOr relAPsINg-remIttImg multIPle sclerOsIs
Meletiche D.M.1, Park S.2, Rutkowski T.2, Chowdhury C.A.2, Beckerman R.2
1EMD Serono, Inc., Rockland, MA, USA, 2CBPartners, New York City, NY, USA
Objectives: To quantify the number and costs of relapses avoided over 2 
years in the first-line treatment of RRMS based on the findings of the Cochrane 
report. MethOds: An Excel-based financial model estimated the relapses and costs 
incurred by a hypothetical cohort of 1000 RRMS patients treated with first-line 
disease-modifying drugs (DMDs). The modelled cohort evaluated the consequences 
of treatment with subcutaneous (SC) interferon beta-1a versus intramuscular 
(IM) interferon beta-1a, as this was the only comparison whose data quality was 
assessed as ‘high’ by the Cochrane Review (Filippini et al., 2013). Risk of relapse 
was based on the 2-year data from the Cochrane Review network meta-analysis. 
The analysis was performed from a US payer perspective. The cost of a relapse was 
sourced from Panitch et al., 2005, and adjusted to 2012 US dollars. Net annual cost 
of therapy was based on wholesale acquisition cost. Given the model’s short time 
horizon, disability-related costs were not included as these tend to be an important 
economic driver only over the long-term progression of the disease. In order to test 
how variability in the model’s inputs might impact the analysis’ results, two-way 
sensitivity analyses were performed based on the reported 95% risk of relapse cred-
ible intervals for SC interferon beta-1a and IM interferon beta-1a. Results: In a 
hypothetical cohort of 1000 RRMS patients, treatment with SC interferon beta-1a 
is expected to result in the avoidance of 173 (sensitivity analysis range: -20 to 399) 
relapses versus IM interferon beta-1a over 2 years. Assuming a direct cost of relapse 
of $5141, this represents a savings of $890,212 (sensitivity analysis range: -$102,138 
to $2,052,934) versus IM interferon beta-1a. cOnclusiOns: Subcutaneous inter-
feron beta-1a is likely to result in fewer relapses and lower direct costs of relapse 
versus IM interferon beta-1a over a 2-year period treatment.
PND13
POteNtIAl BuDget ImPAct Of INtegrAtINg tAlIglucerAse AlfA therAPy 
fOr gAucher DIseAse IN the uNIteD stAtes
Liu L., Pappadopulos E.
Pfizer, New York, NY, USA
Objectives: Gaucher disease (GD), a lysosomal storage disorder caused by muta-
tions in the gene encoding the enzyme glucocerebrosidase, requires life-long treat-
ment with enzyme replacement therapy (ERT). Currently available ERTs include 
imiglucerase, velaglucerase alfa, and taliglucerase alfa. Taliglucerase alfa is the first 
plant cell-expressed beta-glucocerebrosidase ERT approved for adults with type 
1 GD. The purpose of this analysis was to model the potential budget impact of 
taliglucerase alfa therapy for GD in the United States. MethOds: A hypothetical 
budget impact model analysis was performed, based on total estimated number of 
GD patients treated, treatment costs, and estimated treatment distribution of each 
ERT. Costs in USD ($) per 200-unit vial were based on wholesale acquisition costs on 
ReadyPrice and Medi-Span databases. Annual costs were calculated using number 
of vials required. Actual cost savings may vary with factors beyond drug acquisition 
costs (eg, rebate programs) and may not reflect actual costs paid. Results: The 
estimated number of GD patients treated with ERT in the United States was 3,000. 
Drug costs for 200 units of ERT were: taliglucerase alfa–$595, velaglucerase alfa–$675, 
and imiglucerase–$793. Annual costs/patient were estimated at $328,440, $372,600, 
and $437,736 for taliglucerase alfa, velaglucerase alfa, and imiglucerase, respectively. 
Switching 50 patients to taliglucerase alfa, assuming same market share as national 
average, could save up to $4 million annually. The US health care system could 
save ~$100,000/patient annually if patients were switched to taliglucerase alfa. A 
20% increase in the number of patients receiving taliglucerase alfa could translate 
to an overall savings of ~$46 million annually. cOnclusiOns: Taliglucerase alfa 
has the potential to provide a cost-saving alternative to other ERTs. This study was 
sponsored by Pfizer. Editorial support was provided by Peloton Advantage, LLC with 
funding from Pfizer.
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Objectives: Souvenaid® is a medical food - an enriched nutritional formula - that 
contains specific nutrients reported to be deficient in patients with Alzheimer’s 
Disease (AD) and that are important in cognitive function, synapse formation and 
function. Clinical studies demonstrate that dietary management with Souvenaid® 
for 12 to 24 weeks results in a significant improvement in memory in patients with 
early AD. This study aims to estimate the budget impact of Souvenaid® for the 
dietary management of mild AD according to SUS perspective. MethOds: An age 
related incidence of AD approach was used. Population size, according to different 
age categories, was derived from Brazilian statistics (IBGE) and combined to estimate 
the number of patients per age stratum. Average cost of AD was derived from a 
7-state Markov model developed to estimate the effect of Souvenaid® for mild AD 
versus no dietary management (NDM) of mild AD and combined with demographic 
data in each age stratum. Only direct costs, obtained from a public hospital in 
Brazil, were considered. The difference between Souvenaid® group and NDM was 
the 5-year budget impact estimated for SUS. Results: Considering a market pen-
etration of 10%, 13%, 15%, 17% and 20% each year, the estimated number of patients 
under Souvenaid® treatment is 11.002, 15.733, 19.969, 24.894 and 32.216, respectively, 
for years 1-5. Compared to NDM, the inclusion of Souvenaid® in the protocol of mild 
Objectives: Triptan medication use is contraindicated in adults with migriane who 
have cardiovascular disease or cardiovascular (CV) risk factors (i.e., hypertension, 
diabetes, hyperlipidemia, and obesity). The objective of this study is to compare 
Triptan use among Migraineurs with and without cardiovascular disease (CVD) or 
CVD risk factors such as those with diabetes, hypertension, hyperlipidemia, and 
obesity. MethOds: This is a retrospective cross-sectional study using data from 
2009 and 2011 Medical Expenditure Panel Survey (MEPS). The study sample con-
sisted of adults with migraine aged 22-64 years and alive during the calendar years 
(N = 1,142). Chi-square tests were used to compare rates of Triptan use among 
adults with and without CVD/CVD risk factors. Multiple logistic regressions were 
used to compare the likelihood of Triptan use among Migraineurs with and without 
CVD/CVD risk factors. All analyses accounted for the complex survey design of the 
MEPS. Results: Among adult Migraineurs, 26.3% with CVD/CVD risk and 34.3% 
without CVD reported Triptan medication use. After controlling for gender, age, 
race/ethnicity, marital status, education, employment, income level, insurance and 
medication coverage, perceived physical and mental health, current smoking and 
exercise, adults with CVD/CVD risk were less likely to use Triptans compared to 
adults without CVD/CVD risk. (Adjusted Odds Ratio: 0.59, 95% Confidence Interval 
[0.43-0.82]). cOnclusiOns: Although adults with CVD/CVD risk were less likely 
to report Triptan use compared to adults without CVD/CVD risk, nearly 26% of 
Migraineurs with CVD/CVD risk reported Triptan use. The study findings suggest 
that Triptan medication use among adults with CVD/CVD risk is not consistent with 
recommended clinical guidelines.
NeurOlOgIcAl DIsOrDers – cost studies
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sclerOsIs
Mauskopf J.A.1, Fay M.2, Iyer R.3, Livingston T.2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Biogen Idec, Weston, MA, USA, 3Biogen 
Idec, Cambridge, MA, USA
Objectives: To estimate the budget impact of adding delayed-release dimethyl 
fumarate, a new oral drug indicated for the treatment of relapsing forms of mul-
tiple sclerosis (MS) to a managed care formulary in the US. MethOds: An Excel 
model was developed to compare the drug-related costs of the current mix of treat-
ments with the costs of an estimated treatment mix including delayed-release 
dimethyl fumarate for a managed care organization (MCO) with 1,000,000 covered 
lives. The number of people with relapsing forms of MS was estimated using pub-
lished prevalence data. Market share of delayed-release dimethyl fumarate was 
assumed to increase from 10% in 2013 to 25% in 2017 taken proportionately by 
market shares from all other DMTs. Drug costs included acquisition costs adjusted 
by patient payments and dispensing fees as well as administration, monitoring 
and adverse event costs. Annual relapse treatment costs were estimated using the 
relative risk reduction of a relapse for each DMT derived using a mixed-treatment 
comparison analysis. A one-way sensitivity analysis was performed. Results: 
The estimated budget impact of adding delayed-release dimethyl fumarate to 
the formulary was negative for the first 5 years: in 2014, with a market share of 
13.0%, the estimated budget decrease was 0.29% of the total annual costs for 
DMT-related and relapse treatment costs and a decrease of $0.011 per member 
per month (PMPM); in 2017, with a market share of 25.0%, the estimated budget 
decrease was 0.50% of the total annual costs and a decrease of $0.018 PMPM. 
Sensitivity analyses showed that the model was most sensitive to the acquisi-
tion costs of delayed-release dimethyl fumarate. cOnclusiOns: Under model 
assumptions for market shares, adding delayed-release dimethyl fumarate to the 
MCO formulary would result in a small decrease in MCO costs for patients with 
relapsing forms of MS.
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BuDget ImPAct ANAlysIs Of usINg AmylOID POsItrON emIssION 
tOmOgrAPhy (Pet) IN the DIAgNOsIs Of AlzheImer’s DIseAse (AD) IN the 
uNIteD stAtes
Hernandez L.1, Guo S.1, Sandor S.2
1Evidera, Lexington, MA, USA, 2Piramal, Boston, MA, USA
Objectives: In 2013, the Amyloid Imaging Taskforce (AIT) proposed that individuals 
with unexplained mild-cognitive impairment, possible AD, and early-onset demen-
tia are potentially appropriate for amyloid PET in the diagnosis of AD and other 
forms of dementia. This analysis quantified the budgetary impact of using amyloid 
PET according to the AIT’s criteria from the US payer perspective. MethOds: An 
Excel-based model was developed for this analysis. The model projects the number 
of patients eligible for amyloid PET over a 3-year time horizon and calculates the 
incremental cost of using amyloid PET by considering direct medical resource uses 
for diagnostic work-up, dementia medications, and dementia care for patients stay-
ing in communities or institutions. Amyloid PET’s cost could be potentially offset by 
reducing diagnostic work-up time and resources use, unnecessary dementia treat-
ments and delaying disease progression and time to institutional care. The model 
was mainly populated with data from claims data analysis (Truven MarketScan® 
2007–2012) and a survey of 75 dementia practitioners in the US, supplemented 
with data from literature, public databases, and assumptions. All costs were esti-
mated in 2013 dollars. Results: Assuming an uptake of 5% incrementally each 
year, using amyloid PET increased the total cost by about $560,000 to $1,140,000 
per 1 million covered lives over 3 years (or $0.016 to $0.032 per member per month) 
when amyloid PET’s cost was set between $2,500 and $6,000 per scan. Amyloid PET’s 
cost was partially offset by reductions in diagnostic work-up time and resources 
use and costs of institutional care due to more timely and accurate diagnosis and 
treatment. These results were most sensitive to variations in the cost of amyloid 
PET and time horizon. cOnclusiOns: Using amyloid PET in the diagnosis of AD 
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the multiplier effect. This novel approach highlighted the unique characteristics 
of Alzheimer’s disease with particular focus on the additional costs and societal 
impact stemming from caring for a patient with Alzheimer’s. Future cost effective-
ness studies need to consider these additional impacts when quantifying their 
results and potential benefit to the health care system. Approaches to modelling 
long term disease impact must therefore be expanded to consider the wide reaching 
societal impact of Alzheimer’s disease to the direct health care costs.
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treNDs IN ANtI-ePIlePtIc ADjuNctIve therAPy utIlIzAtION AND cOsts 
frOm 2006-2011: AN ANAlysIs Of A lArge ADmINIstrAtIve clAIms 
DAtABAse
Velez F.F.1, Menzin J.2, Munsell M.2, Frean M.2
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Objectives: To evaluate patterns of adjunctive therapy with anti-epileptic drugs 
(AED) and AED-specific pharmacy costs among patients with epilepsy over a six-
year time period (2006-2011). MethOds: Study patients were identified from the 
2006-2011 PharMetrics Plus Database. Separate patient cohorts were created for each 
year of analysis. Patients ≥ 18 years of age with ≥ 2 claims for epilepsy (ICD-9-CM 
345.XX) who were continuously eligible for the entire calendar year were selected. 
Demographic characteristics, proportion of patients with adjunctive AED therapy 
(defined as a ≥ 60 day overlap in supply for two different AEDs) and AED phar-
macy costs were evaluated for each calendar year. Overall adjunctive AED therapy 
utilization was further stratified by AED generic/brand status using the following 
categories: adjunctive therapy with two generic AEDs, two branded AEDs, or one 
generic and one branded AED. AEDs were identified and categorized based on NDC 
codes indicative of a generic/branded therapy for each year. Results: Patients 
meeting cohort selection criteria varied for each year of analysis, ranging from 
28,013 to 61,444 (mean age 44.6-46.3 years). The proportion of patients on adjunc-
tive AED therapy stayed relatively constant over the analysis period, increasing only 
slightly over time (2006: 21.2%, 2007: 24.1%, 2008: 23.9%, 2009: 23.9%, 2010: 24.6%, 
2011: 24.7%). Adjunctive generic AED therapy utilization approximately doubled 
over the analysis period (2006: 11.5%, 2011: 21.7%), while branded therapy decreased 
5-fold (2006: 3.1%, 2011: 0.6%) and generic/branded decreased by > 50% (2006: 11.1%, 
2011: 4.9%) adjunctive AED therapy decreased (all P< 0.01). Over the six-year analysis 
period, mean AED pharmacy costs among patients with epilepsy on any adjunctive 
AED therapy decreased by 7.6% (2006: $4,090, 2011: $3,778; P< 0.01). cOnclusiOns: 
In this study, a doubling in the utilization of generic drugs over a six-year period 
was associated with a 7.6% decrease in pharmacy cost.
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Objectives: Because of the risk of progressive multifocal leukoencephalopathy 
(PML), natalizumab is generally recommended as second-line treatment for relaps-
ing-remitting multiple sclerosis (RRMS) patients. For those negative for anti-JC virus 
antibodies, the natalizumab associated risk of PML is low. The objective was to 
estimate the cost-effectiveness of first-line natalizumab versus second-line natali-
zumab treatment (i.e., initiate glatiramer acetate (GA) then switch to natalizumab) 
for RRMS patients negative for anti-JC virus antibodies. MethOds: We used a cohort 
simulation model to estimate the 20-year costs and outcomes of first- and second-
line natalizumab treatment. Model inputs included published natural history pro-
gressions of the Expanded Disability Status Scale (EDSS), treatment effects from 
randomized controlled trials on disease progression and relapse rates, risk of PML, 
and utilities. We used the PharMetrics Plus claims database for total costs, switching 
and discontinuation rates and their associated costs (i.e., first-line treatment with 
GA then switch or discontinue). Outputs for the average patient, discounted at 3% 
per annum, were quality-adjusted life years (QALYs), costs in 2012 US dollars, and 
incremental cost-effectiveness ratios (ICERs). Results: Compared to natalizumab 
as second-line treatment after switching from GA, first-line natalizumab treatment 
was associated with 0.40 incremental QALYs gained, $36,779 more in 20-year costs 
for an ICER of $91,510 per QALY. Compared to first-line GA treatment without switch-
ing, first-line treatment with natalizumab was associated with an ICER of $95,764 
per QALY (likelihood = 0.56 that first-line natalizumab treatment was cost-effective 
at a willingness-to-pay of $100,000 per QALY). First-line natalizumab treatment 
dominated second-line natalizumab treatment when compared to GA treatment 
without switching through principles of extended dominance. cOnclusiOns: 
Treating JC virus negative RRMS patients with natalizumab as a first-line treatment 
provided better value compared to natalizumab use as a second-line agent. More 
aggressive treatment with natalizumab should be considered for RRMS patients 
who are negative for anti-JC virus antibodies.
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cOst-effectIveNess Of fINgOlImOD, terIfluNOmIDe, DImethyl 
fumArAte AND INtrAmusculAr INterferON BetA-1A IN relAPsINg-
remIttINg multIPle sclerOsIs
Zhang X., Hay J.W.
University of Southern California, Los Angeles, CA, USA
Objectives: To compare the cost-effectiveness of fingolimod, teriflunomide, dime-
thyl fumarate and IM IFN β -1a as first-line therapies in treatment of patients with 
Relapsing-Remitting Multiple Sclerosis (RRMS). MethOds: A Markov model was 
developed to simulate the disease progression and to evaluate the cost-effectiveness 
of disease-modifying drugs from a US societal perspective. The time horizon in base 
AD shows a potential budget impact of approximately Brz3,9 million (US$1,8 million) 
for 5 consecutive years. cOnclusiOns: The use of Souvenaid®, a new approach 
in the management of mild AD, can benefit approximately 100.000 patients with 
AD in 5 years and it is estimated to have a relatively small budget impact to SUS, 
since the projections of cost of disease for the same period are Brz154 million and 
potential budget impact of approximately Brz3,9 million.
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Objectives: Parkinson´s disease is a neurodegenerative disorder with an estimated 
incidence of 40-50 cases per 100,00 habitants per year. In this paper, We set out to 
estimate the direct medical costs of Parkinson´s disease. In addition, direct medical 
costs according to age, gender, socio-economic level, severity and educational attain-
ment were evaluated. MethOds: A partial economic evaluation was performed in 
order to analyse the direct medical costs related to Parkinson´s disease. The analysis 
took the perspective of the National Institute of Neurology and Neurosurgery (INNN) 
for the first semester of 2013, including outpatient clinic visits, medications, medi-
cal procedures and laboratory tests, these costs were provided from the INNN´s 
financial managment. A mexican retrospective study of patients having Parkinson´s 
disease from the INNN provided information on severity, baseline characteristics 
and socio-demographic characteristics. Results: Mean first semester direct medi-
cal costs per patient on Parkinson´s disease were US$2 366 in 2013. When analyz-
ing cost distribution, no differences were found in the direct medical costs for 
the modality groups. In severity and gender, costs hadn´t statistical significance 
(p-value> .05). On the other hand, costs by grouped age, grouped socio-economic 
level and educational attainment were statistically different (p-value< .001). Finally, 
in the generalized linear model analysis, direct medical costs were only predicted by 
grouped socio-economic level; age, gender, severity or years of schooling weren´t sta-
tistically sgnificance in the model. cOnclusiOns: The first semester direct medical 
costs per patient on Parkinson´s disease in this study were US$2 366 in 2013. Total 
direct medical costs by grouped age and educational attainment were statistically 
different for patients having Parkinson´s disease. In a multivariate analysis, only 
socio-economic level predicted a higher direct medical cost.
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cOst Of mANAgINg PArkINsON’s DIseAse IN chINA
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Objectives: To review studies that investigated the direct and indirect costs of care 
for Parkinson’s disease (PD) in China. MethOds: A structured literature review 
on published articles in both English and Mandarin languages was conducted. 
Literature search was conducted using PubMed, Cochrane, WAN FANG, and VIP 
databases. Articles published between 2000 and 2013 were selected. The inclusion 
criteria included studies on Chinese population based in China only and studies that 
reported direct or indirect cost of PD treatment, management as well as economic 
burden of PD. Four reviewers (two for each language) independently selected and 
reviewed the articles. Subjective quality assessment of the selected articles were 
performed. Direct cost included cost of outpatient consultation, hospitalisation, 
medication, rehabilitation and the use of prescribed traditional Chinese medicine; 
whereas indirect cost included home care, transport, home support equipment, 
supplement use, and productivity loss. Results: Eleven articles (10 Mandarin and 1 
English) were selected and reviewed qualitatively. Approximately 80% of the articles 
reviewed received an average grade in terms of study quality. The average direct 
and indirect cost of managing PD in China reported ranged from RMB 7,000 (USD 
1,157) to RMB 15,000 (USD 2,479) per annum. The reported direct cost of managing 
PD ranged from RMB 1,600 (USD 265) to RMB 13,000 (USD 2,149); whereas the indirect 
cost reported ranged from RMB 2,970 (USD 491) to RMB 13,200 (USD 2,182). Seven 
out of 11 articles reported cost-effectiveness results. Three papers from the same 
authors had reported the main factors affecting the overall economic burden of 
PD. cOnclusiOns: Various combination therapy involving levodopa had higher 
direct costs but reduced indirect costs compared to levodopa monotherapy. In gen-
eral, the reported indirect cost is higher than direct cost of PD management in China.
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estImAte Of the INDIrect BurDeN Of AlzheImer’s
Sigmundsson B., Brown D., Kopenhafer L., Ghouse R., Haines P.
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Objectives: To estimate the indirect burden of Alzheimer’s disease in 
US. MethOds: Applying the economic concept of the multiplier effect – the degree 
to which a change in aggregate demand may have a greater effect on national 
income – to the analysis of the indirect cost of Alzheimer’s disease can provide 
valuable insights to the societal burden of the disease. US demography forecasts and 
disease incidence rates were used to develop a Markov model for the Alzheimer’s 
patient population. Estimates for the indirect cost of Alzheimer’s were derived 
using key variables, such as hours spent on care per patient, severity of the illness, 
percentage in need of care by disease severity, and salaries. Results: The model 
predicted that the indirect burden of Alzheimer’s will increase by 85% from 2015-
2020, by 33% from 2020 to 2025 and by 17% from 2025-2030. The main cost drivers in 
the model are the unpaid work by carers and lost revenues due to mild Alzheimer’s 
patients having to leave the labor market. cOnclusiOns: By employing the mul-
tiplier model it was determined that the indirect costs attributed to Alzheimer’s 
disease have a significant impact on the total burden of the disease, due in part to 
